Back

Corrigendum to: Treatment of Fabry Disease management with migalastat—outcome from a prospective 24 months observational multicenter study (FAMOUS)

European Heart Journal - Cardiovascular Pharmacotherapy

12 October 2021
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Congress Presentation
Safety and efficacy of migalastat in Fabry's disease treatment with cardiac impact : a systematic review and meta-analysis
29 August 2025
thumbnail
Congress Presentation
Mid-term benefit of pharmacological chaperone therapy on cardiac manifestation in Japanese Fabry disease
29 August 2025
thumbnail
Congress Presentation
Successful radiofrequency ablation of ventricular tachycardia storm in late-onset anderson-Fabry disease
7 April 2024
thumbnail
Congress Presentation
Long-term clinical-pathologic results of enzyme replacement therapy in pre-hypertrophic Fabry disease cardiomyopathy
25 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources